Labcorp and Quest lead the market for longevity testing services because they already run large lab networks, offer broad blood panels, and connect results with consumer health tools. That makes them easier to use than small testing startups. It does not make every “biological age” claim proven.
That is the first fact worth keeping in view.
Labcorp sells a Healthy Aging Test through Labcorp OnDemand. The panel includes common blood measures, such as a complete blood count, metabolic markers, thyroid tests, vitamin levels, cholesterol, insulin, inflammation markers, hemoglobin A1c, and apolipoprotein B. Labcorp also lists a larger Longevity and Vitality Panel for health professionals.
Quest offers health profiles through Quest Health. These panels cover many routine blood measures and can be ordered through its consumer platform. Quest also has a large national network, with about 2,000 patient service centers.
Those facts matter more than a clever score.
A longevity test often starts with ordinary lab work. The results may show blood sugar, cholesterol, kidney function, liver function, blood counts, thyroid activity, or signs of inflammation. These are real health measures. They can help describe present health risks. They do not show how long someone will live.
That line gets blurred in marketing.
A company may take many lab results and turn them into one number called biological age. The number may look exact. It may say that a person is older or younger than their calendar age. The math can be useful for research. The number can also create more confidence than the evidence allows.
Quest now offers a biological age add-on from Humanity for some health profiles. The service uses routine lab results to estimate biological age. It also breaks the result into body systems, such as heart, liver, kidney, blood, immune, hormone, and bone health.
The product is a report. It is not a crystal ball.
A score can track changes in the numbers used to create it. That does not prove longer life, better health, or lower disease risk. A lower inflammation marker may be useful. A lower score may still fail to predict what happens to one person over time.
The evidence problem is simple. Aging is not one process that appears in one blood number. It involves many body systems. A useful aging marker must do more than match age. It must help predict meaningful outcomes, such as function, disease, or survival. It should also help guide care or improve results.
Researchers have not reached that standard for aging biomarkers in routine medical care. Reviews of the field say no aging biomarker has yet gained approval from U.S. regulators for clinical use. They also point to a lack of long-term trials showing that these scores improve how people feel, function, or survive.
That does not make the tests worthless. It makes the claim smaller.
Routine lab panels can provide useful information about known health risks. They may reveal a result that deserves a proper medical review. They can also create a baseline for tracking ordinary measures over time. Those are modest claims. Modest claims are often the honest ones.
The trouble starts when a company moves from “this test measures a marker” to “this test measures your aging.” The second statement needs much stronger proof.
There is another issue: more data can produce more noise. A large panel may include dozens of values. Some change with food, sleep, exercise, stress, infection, medication, or the time of day. A result outside the reference range may have several causes. A result inside the range may not rule out a problem.
A report can list a concern without explaining what it means for a real person. That is where clinical judgment matters. A consumer dashboard cannot replace the context of symptoms, history, family risk, and repeat testing.
The business model also deserves a plain look. Labcorp and Quest have an advantage because they control the basic testing step. They collect the sample, run many of the measurements, and can sell extra reports on top. This creates a smooth customer path. It also gives the companies a strong role in deciding which numbers deserve attention.
Convenience is not validation.
A smaller longevity company may offer an epigenetic clock, a genetic risk report, a fitness score, or an AI summary. Some tools are based on human studies. Others rely on early research, animal work, cell studies, or company models. Those forms of evidence are not equal.
Animal and cell findings can help researchers form ideas. They do not prove that a consumer test changes human health. A study that links a marker with age does not prove that changing the marker will slow aging. A model trained on one group may work less well in another group.
This is why Labcorp and Quest lead the service category, but not because they have solved longevity science. They lead because they offer scale, familiar blood testing, broad menus, and easier access. Quest has also moved into biological age reports through a partner. Labcorp has built a clear healthy-aging panel around standard measures.
The best part of these services is the ordinary lab work. The weakest part is often the grand story placed around it.
I would read a longevity report in that order. First, separate the actual measurements from the score. Next, separate a company claim from a result shown in long human studies. Then ask what action the score changes. If the answer is unclear, the score may be interesting without being useful.
Price matters too, but price alone does not show value. A low-cost panel can still create needless worry. A costly report can still restate information from common tests. The key question is not how many biomarkers appear on the page. It is whether each measure has a clear purpose and a reliable path to interpretation.
That standard will likely change as research improves. Long studies may show that some markers predict function or disease better than others. New tools may help researchers test treatments faster. But “promising” is still not the same as “proven.”
For now, Labcorp and Quest are the strongest practical names in longevity testing services. Their advantage is access to broad, routine blood testing. Their limit is the same limit facing the whole field: no blood panel can yet prove how fast one person is aging or how long that person will live.
That is the fact I would keep beside every biological age score. The people, products, claims, and technologies shaping longer life are worth watching. LifeX Signal is built around that same question, with the marketing trimmed down to the evidence that can actually carry it.
More on: Longevity Products and Business